Skip to main content
Premium Trial:

Request an Annual Quote

Instrument Sales, Contracts Help Double Cepheid's Q3 Revenue

NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 53 percent as R&D spending rose 50 percent and its net loss increased around 19 percent.
Total receipts for the three months ended Sept. 30 increased to $36.3 million from $23.8 million year over year.
Cepheid said instrument sales rose around 118 percent to $15.9 million; reagent and disposable sales increased 18 percent to $18.1 million; contract revenues more than doubled to $2 million; and government and government-sponsored research revenue rose 125 percent to $289,000.
Cepheid CEO John Bishop said third-quarter results were driven by GeneXpert sales. He also suggested that tests the firm is developing in addition to its molecular-based test for methicillin-resistant Staphylococcus aureus will be in demand due to the "significant problem" of healthcare-acquired infections.
Cepheid’s R&D spending rose to $8.4 million from $5.6 million year over year.
The company said its third-quarter loss rose to $4.7 million from $4 million in the year-ago period.
Cepheid said it had around $8.3 million in cash and cash equivalents, and $33.1 million in marketable securities as of Sept. 30.
The company projected total revenues for fiscal year 2007 to be in the range of $124 million to $127 million.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.